We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research use, and the firm maintains research partnerships with large biopharmaceutical companies. The company offers Guardant 360, a blood-based (liquid biopsy) test for treatment selectio... Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research use, and the firm maintains research partnerships with large biopharmaceutical companies. The company offers Guardant 360, a blood-based (liquid biopsy) test for treatment selection in advanced stage cancer, and Guardant Omni, a broader gene panel for immuno-oncology research. The company's pipeline includes Guardant Reveal (formerly Lunar-1), for cancer recurrence detection in survivors, and Lunar-2, a liquid biopsy for early detection of cancer in higher-risk individuals, with an initial focus on colorectal cancer. Additionally, Guardant offers research development services. The United States accounts for 90% of total revenue, and other markets the remaining 10%. Show more
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the Molecular and Clinical Genetics Panel of the U.S. Food and Drug Administration Medical Devices...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the first quarter 2024 after market close on Thursday, May 9, 2024...
New research demonstrates value of epigenomic analysis and methylation sequencing with Guardant liquid biopsy portfolio across continuum of cancer care New data show strong performance of...
Study shows blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% Results pave the way for first potential FDA-approved blood test for colorectal...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on February 15, 2024, the Compensation Committee of Guardant’s Board of Directors approved the...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.632 | 3.86780905753 | 16.34 | 18.27 | 15.81 | 1795834 | 17.16643432 | CS |
| 4 | -1.228 | -6.74725274725 | 18.2 | 22.27 | 15.81 | 2442036 | 18.67447775 | CS |
| 12 | -5.038 | -22.8895956383 | 22.01 | 23.36 | 15.81 | 1996671 | 19.34213927 | CS |
| 26 | -8.618 | -33.6772176631 | 25.59 | 30.36 | 15.81 | 1805202 | 22.14215023 | CS |
| 52 | -5.878 | -25.7242888403 | 22.85 | 41.06 | 15.81 | 1852586 | 27.17311124 | CS |
| 156 | -142.948 | -89.3871935968 | 159.92 | 169.425 | 15.81 | 1451148 | 47.59011206 | CS |
| 260 | -48.138 | -73.9333435724 | 65.11 | 181.07 | 15.81 | 1287162 | 63.25027449 | CS |
DewDiligence
1 year ago
jerseyboy
3 years ago
jerseyboy
3 years ago
jerseyboy
3 years ago
PR_12
3 years ago
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
